Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Market Analysis
Anxiety disorders drug market likely to decrease from $4.5 billion to $2.6 billion by 2015
May 18th, 2006
The global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 primarily due to the launch of numerous generic anxiety drugs from 2006 onwards. The influx of generic anxiety drugs will offset the revenue growth derived from existing drugs seeking additional anxiety indications, and the launch of several novel anxiety drugs, according to a research report, "Anxiety Disorders - A Decade of Declining Revenues," released by Research and Markets. The reported includes an analysis for key products in development for GAD (generalized anxiety disorder), SAD (social anxiety disorder), OCD (obsessive-compulsive...
Source: Biotech Business Week (2006-05-18)
|
